Redhill Biopharma Stock Current Valuation
Valuation analysis of RedHill Biopharma helps investors to measure RedHill Biopharma's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
RedHill Biopharma Company Current Valuation Analysis
RedHill Biopharma's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current RedHill Biopharma Current Valuation | 76.08 M |
Most of RedHill Biopharma's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, RedHill Biopharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
CompetitionIn accordance with the recently published financial statements, RedHill Biopharma has a Current Valuation of 76.08 M. This is much higher than that of the sector and significantly higher than that of the Current Valuation industry. The current valuation for all United States stocks is notably lower than that of the firm.
RedHill Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses RedHill Biopharma's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of RedHill Biopharma could also be used in its relative valuation, which is a method of valuing RedHill Biopharma by comparing valuation metrics of similar companies.RedHill Biopharma is currently under evaluation in current valuation category among related companies.
RedHill Fundamentals
| Return On Equity | -246.27 | |||
| Return On Asset | -32.82 | |||
| Profit Margin | (142.81) % | |||
| Operating Margin | (123.49) % | |||
| Current Valuation | 76.08 M | |||
| Shares Outstanding | 234.96 M | |||
| Shares Owned By Insiders | 4.94 % | |||
| Shares Owned By Institutions | 0.20 % | |||
| Price To Earning | (4.01) X | |||
| Price To Book | 0.87 X | |||
| Price To Sales | 3.70 X | |||
| Revenue | 44.49 M | |||
| Gross Profit | 4.03 M | |||
| EBITDA | (50.19 M) | |||
| Net Income | (63.53 M) | |||
| Cash And Equivalents | 34.79 M | |||
| Cash Per Share | 0.93 X | |||
| Total Debt | 85.89 M | |||
| Debt To Equity | 2.99 % | |||
| Current Ratio | 1.80 X | |||
| Book Value Per Share | 0.77 X | |||
| Cash Flow From Operations | (49.74 M) | |||
| Earnings Per Share | (1.80) X | |||
| Number Of Employees | 155 | |||
| Beta | 1.62 | |||
| Market Capitalization | 164.63 M | |||
| Total Asset | 49 M | |||
| Retained Earnings | (82 M) | |||
| Working Capital | 36 M | |||
| Current Asset | 43 M | |||
| Current Liabilities | 7 M | |||
| Z Score | -4.1 |
Currently Active Assets on Macroaxis
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.
Other Consideration for investing in RedHill Pink Sheet
If you are still planning to invest in RedHill Biopharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the RedHill Biopharma's history and understand the potential risks before investing.
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Money Managers Screen money managers from public funds and ETFs managed around the world |